Lundbeck Seattle Biopharmaceuticals

Bob Azelby to join Cardinal Health Board of Directors

Retrieved on: 
Wednesday, February 28, 2024
Amgen, Cardinal Health, MBA, ADC, Juno Therapeutics, University, Therapy, Organization, CAH, Harvard Business School, Religious studies, Clovis Oncology, Lundbeck Seattle Biopharmaceuticals, Management

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.

Key Points: 
  • DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
  • Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
  • Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics.
  • "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health.

Harpoon Therapeutics Strengthens Leadership Team

Retrieved on: 
Tuesday, December 26, 2023
Shearman & Sterling, Harpoon, Shearman, Accounting, Human, Talent management, Lundbeck Seattle Biopharmaceuticals, Intellectual property, Law, SAN, Therapy, Exelixis, University, Culture, General counsel, Growth, Human resources, Colgate University, Gilead Sciences, Employment, Management

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D.
  • Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer.
  • “I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy’s promotion.
  • In connection with Mr. Bucher’s appointment, Harpoon Therapeutics granted him an inducement non-qualified stock option to purchase an aggregate of 110,000 shares of Harpoon’s common stock.

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
Thursday, November 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

Zymeworks Appoints New Director

Retrieved on: 
Thursday, June 29, 2023
Lundbeck Seattle Biopharmaceuticals, Lundbeck, Culture, Allergan, Eptinezumab, Eli Lilly, Organization, Acquisition, Patient, Cancer, Eli Lilly and Company, Therapy, Management, Zymeworks, Indiana University

Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors.

Key Points: 
  • Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors.
  • Mr. Campoy succeeds Dr. Natalie Sacks, who will step down effective as of June 30 after a successful 6-year tenure as board director of Zymeworks.
  • “The entire Zymeworks’ board of directors and employees are sincerely grateful to Dr. Sacks for her dedicated service to Zymeworks.
  • Egon Zehnder, a global leadership advisory firm, was actively engaged with Zymeworks in an advisory capacity and assisted in the recruitment of Mr. Campoy to the Zymeworks’ board of directors.

Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Tuesday, May 9, 2023
ERA, Congress, Investigational New Drug, Patient, Focal segmental glomerulosclerosis, Merck, Diabetic nephropathy, Alport syndrome, Proteinuria, Primary hyperoxaluria, MAD, FDA, IND, Safety, Lundbeck Seattle Biopharmaceuticals, LDHA, European Renal Association, ASSIST, Cohort, FSGS, ETA, Kidney, IgA nephropathy, Juno Therapeutics, Research, Therapy, Type D, Juno, SC, Nephrology, Clinical trial, SAD, Part, SGLT2, Immunoglobulin A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic kidney disease, Food, Pharmaceutical industry, Atrasentan, Chinook

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.

Key Points: 
  • SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.
  • “During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases.
  • Chinook plans to present data from one or more additional cohorts of the AFFINITY trial in the second half of 2023.
  • Revenue – Revenue for the quarter ended March 31, 2023 was $1.8 million compared to $2.7 million for the same period in 2022.